Movano Health Announces Blood Pressure Partnership Forum Following Significant Response to Groundbreaking Accuracy Achievement

News provided by

Dec 12, 2023, 12:00 ET

PLEASANTON, Calif., Dec. 12, 2023 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced that following the successful results of its recent blood pressure clinical trial it will be holding in person demonstrations of live waveforms at both the 2024 CES Show in Las Vegas January 8-11, 2024 and in conjunction with the JP Morgan Healthcare Conference in San Francisco January 9-10, 2024.

Movano's proprietary and patented System-on-a-Chip, the smallest ever custom RF-enabled IC designed for blood pressure or glucose monitoring.

Designed to showcase Movano Health's System on a Chip (SoC) and illustrate the strategic ways this technology can be implemented to monitor multiple chronic conditions, these events will be an opportunity for prospective partners to experience the efficacy of the recent clinical trial results and, if desired, under NDA review the development roadmap.

"The response to our recent blood pressure clinical trial results has far exceeded our expectations and as we transition to the next phase of development including undergoing critical pivotal trials, we believe it is the right time to open up the conversation to potential partners," said Michael Leabman, CTO and Founder of Movano Health. "Our goal is to significantly accelerate the development and commercialization of this technology and help millions of people as quickly as possible."

During the recent trial, Movano Health's cuffless prototype showed a level of accuracy within the standards recognized by the FDA for blood pressure monitoring devices. The prototype achieved an overall mean absolute difference (MAD) of 5.9 mmHg, which is below the 7 mmHg MAD required per a standard for wearable, cuffless blood pressure measuring devices (IEEE1708a-2019). Movano Health is also evaluating AI-based individual calibration methods to further enhance the future performance of the device.

Movano Health's ultra-compact System-on-a-Chip (SoC) measures just 4 x 6.7mm and is the culmination of five years of intensive research, centering on advanced mmWave Radio Frequency (RF) and AI technology, leading to 23 issued patents and 31 pending.

"Blood pressure monitoring will be a significant addition to the suite of analytes we currently offer in our recently launched product, the Evie Ring", said John Mastrototaro, CEO of Movano Health. "We are excited to continue to build a robust data collection and evaluation solution to help people take better care of their overall health."

For more information about participating in the blood pressure partnership forum, please contact Michael Soule, VP of Business Development, at [email protected] as soon as possible, as time slots will fill up quickly.

About Movano Health
Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health is developing a suite of purpose-driven healthcare solutions to bring medical-grade, high-quality data to the forefront of consumer health devices. Featuring modern form factors, Movano Health's devices capture a comprehensive picture of a person's vital health information and uniquely translate the data into personalized and intelligent insights that empower consumers to live healthier and more balanced lives. Movano Health's end-to-end solutions will soon enable consumers and their healthcare professionals to utilize daily medical-grade data as a tool to proactively monitor and manage health outcomes. For more information on Movano Health, visit https://movanohealth.com/.

Forward Looking Statements
This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding plans with respect to commercial launch of the Evie Ring; planned cost-cutting initiatives; anticipated FDA clearance for the Evie Ring and other products in development; expected future operating results; product development and features, product releases, clinical trials and regulatory initiatives; our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

SOURCE Movano